Literature DB >> 10701737

Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma.

T Todoroki1, K Ohara, T Kawamoto, N Koike, S Yoshida, H Kashiwagi, M Otsuka, K Fukao.   

Abstract

PURPOSE: The objective of this study was to determine the benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma (Klatskin tumor). METHODS AND MATERIALS: We conducted a retrospective review of 63 patients who underwent surgical resection of Stage IVA Klatskin tumor. Of the 63 patients, 47 had microscopic tumor residue (RT1). Twenty-eight of the 47 patients with RT1 were treated by adjuvant radiotherapy and the remaining 19 patients were treated exclusively by surgical resection. Seventeen of the 28 patients with RT1 were treated by both intraoperative radiotherapy (IORT) and postoperative radiotherapy (PORT); of the remaining 11 patients with RT1, 6 underwent resection and IORT, and 5 underwent resection and PORT.
RESULTS: The major complication and 30-day operative death rates were significantly lower in the radiation group (9.5% and 0.0%, respectively) than in the resection alone group (28.5% and 9.5%, respectively). Of the eight 5-year survivors with RT1, 6 had adjuvant radiotherapy and the remaining 2 had resection alone. Adjuvant radiotherapy for patients with RT1 yielded significantly (p = 0.0141) higher 5-year survival rates (33.9%) than in the resection alone group (13.5 %). The best 5-year survival rate (39.2 %) was found in patients who underwent a combination of IORT and PORT after resection. The local-regional control rate was significantly higher in the adjuvant radiation group than in the resection alone group (79.2% vs. 31.2%).
CONCLUSION: Our data clearly suggest the improved prognosis of patients with locally advanced Klatskin tumor by integrated adjuvant radiotherapy with IORT and PORT to complete gross tumor resection with acceptable treatment mortality and morbidity.

Entities:  

Mesh:

Year:  2000        PMID: 10701737     DOI: 10.1016/s0360-3016(99)00472-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  52 in total

Review 1.  Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.

Authors:  J R A Skipworth; S W M Olde Damink; C Imber; J Bridgewater; S P Pereira; M Malagó
Journal:  Aliment Pharmacol Ther       Date:  2011-09-20       Impact factor: 8.171

2.  Outcome of surgical treatment of hilar cholangiocarcinoma.

Authors:  Kazuhiro Otani; Kazuo Chijiiwa; Masahiro Kai; Jiro Ohuchida; Motoaki Nagano; Kazuyo Tsuchiya; Kazuhiro Kondo
Journal:  J Gastrointest Surg       Date:  2007-12-18       Impact factor: 3.452

3.  Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder.

Authors:  Hiroshi Itoh; Koji Nishijima; Yoshiyuki Kurosaka; Shigeru Takegawa; Masato Kiriyama; Shotaro Dohba; Yasuhiko Kojima; Yasuo Saitoh
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

4.  Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.

Authors:  Clifton D Fuller; Samuel J Wang; Mehee Choi; Brian G Czito; John Cornell; Tania M Welzel; Katherine A McGlynn; Join Y Luh; Charles R Thomas
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

Review 5.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

6.  Hilar cholangiocarcinoma: expert consensus statement.

Authors:  John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

7.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

8.  Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma.

Authors:  Wen-Ke Cai; Jia-Ji Lin; Gong-Hao He; Hua Wang; Jun-Hua Lu; Guang-Shun Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

9.  [Is there a nonsurgical therapeutic approach to cholangiocellular carcinomas?].

Authors:  M Fuchs; W Schepp
Journal:  Chirurg       Date:  2006-04       Impact factor: 0.955

10.  Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study.

Authors:  Kyu-Hyoung Lim; Do-Youn Oh; Eui Kyu Chie; Jin-Young Jang; Seock-Ah Im; Tae-You Kim; Sun-Whe Kim; Sung Whan Ha; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2009-09-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.